Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.

Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA.

Clin Cancer Res. 2018 Sep 26. doi: 10.1158/1078-0432.CCR-18-1129. [Epub ahead of print]

PMID:
30257981
2.

A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice.

Viswanath P, Peng S, Singh R, Kingsley C, Balter PA, Johnson FM.

Neoplasia. 2018 Oct;20(10):975-984. doi: 10.1016/j.neo.2018.08.003. Epub 2018 Aug 26.

3.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J.

Cancer Chemother Pharmacol. 2018 Jun 7. doi: 10.1007/s00280-018-3610-z. [Epub ahead of print]

PMID:
29882016
4.

Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.

Kalu NN, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM.

Cancer Lett. 2018 Sep 1;431:64-72. doi: 10.1016/j.canlet.2018.05.029. Epub 2018 May 25.

PMID:
29807113
5.

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS.

Cancer. 2018 May 15;124(10):2169-2173. doi: 10.1002/cncr.31346. Epub 2018 Mar 26.

PMID:
29579331
6.

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.

Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN Jr, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J.

Mod Pathol. 2018 Jun;31(6):947-955. doi: 10.1038/s41379-018-0029-3. Epub 2018 Feb 6.

PMID:
29410488
7.

Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy.

Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, Garden AS.

Cancer. 2018 Apr 1;124(7):1415-1427. doi: 10.1002/cncr.31235. Epub 2018 Jan 16.

PMID:
29338089
8.

CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition.

Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN.

Cancer Res. 2018 Feb 1;78(3):781-797. doi: 10.1158/0008-5472.CAN-17-2802. Epub 2017 Dec 11.

PMID:
29229598
9.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Kalu NN, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, Johnson FM.

Oncotarget. 2017 Sep 21;8(49):86369-86383. doi: 10.18632/oncotarget.21174. eCollection 2017 Oct 17.

10.

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.

Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA.

Oncotarget. 2017 Sep 1;8(43):73419-73432. doi: 10.18632/oncotarget.20621. eCollection 2017 Sep 26.

11.

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS.

Invest New Drugs. 2018 Jun;36(3):416-423. doi: 10.1007/s10637-017-0513-5. Epub 2017 Oct 19.

PMID:
29047029
12.

Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy.

Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, Rosenthal DI, Garden AS.

Oral Oncol. 2017 Sep;72:90-97. doi: 10.1016/j.oraloncology.2017.07.002. Epub 2017 Jul 16.

13.

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw297.

14.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

15.

Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.

Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM.

Cancer Lett. 2017 Apr 28;392:71-82. doi: 10.1016/j.canlet.2017.01.024. Epub 2017 Jan 23.

16.

Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?

Kalu NN, Johnson FM.

Expert Opin Investig Drugs. 2017 Feb;26(2):207-217. doi: 10.1080/13543784.2017.1274731. Epub 2017 Jan 1. Review.

PMID:
28042706
17.

Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy.

Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN Jr, Beadle BM, Skinner HD, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS.

Head Neck. 2017 Apr;39(4):633-638. doi: 10.1002/hed.24666. Epub 2016 Dec 22.

PMID:
28006086
18.

Identifying mechanisms of change in a conversation therapy for aphasia using behaviour change theory and qualitative methods.

Johnson FM, Best W, Beckley FC, Maxim J, Beeke S.

Int J Lang Commun Disord. 2017 May;52(3):374-387. doi: 10.1111/1460-6984.12279. Epub 2016 Nov 23.

19.

Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.

Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, Freemantle SJ, Dmitrovsky E.

Mol Cancer Ther. 2016 Nov;15(11):2758-2766. Epub 2016 Aug 22.

20.

Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base.

Garden AS, Fuller CD, Rosenthal DI, William WN Jr, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM.

Cancer. 2016 Nov 15;122(21):3411-3412. doi: 10.1002/cncr.30193. Epub 2016 Jul 15. No abstract available.

21.

Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.

Lee SC, Min HY, Jung HJ, Park KH, Hyun SY, Cho J, Woo JK, Kwon SJ, Lee HJ, Johnson FM, Lee HY.

Oncogene. 2016 Oct 20;35(42):5515-5526. doi: 10.1038/onc.2016.92. Epub 2016 Apr 18.

22.

Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.

Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, Kwon SJ, Lee HJ, Ni X, Shin YK, Johnson FM, Duvic M, Lee HY.

Clin Cancer Res. 2017 Mar 1;23(5):1299-1311. doi: 10.1158/1078-0432.CCR-16-0534. Epub 2016 Aug 31.

23.

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.

Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A.

Mol Cancer Ther. 2016 Oct;15(10):2334-2343. Epub 2016 Jul 20.

24.

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.

Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.

Oncotarget. 2016 Jul 26;7(30):47998-48010. doi: 10.18632/oncotarget.10332.

25.

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J.

J Clin Oncol. 2016 May 20;34(15):1764-71. doi: 10.1200/JCO.2015.64.5788. Epub 2016 Apr 4.

26.

Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.

Garden AS, Fuller CD, Rosenthal DI, William WN Jr, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM.

Cancer. 2016 Jun 1;122(11):1702-7. doi: 10.1002/cncr.29965. Epub 2016 Mar 28.

27.

Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.

Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM.

Oncotarget. 2016 Jan 5;7(1):565-79. doi: 10.18632/oncotarget.6376.

28.

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.

Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM.

Clin Cancer Res. 2016 Apr 1;22(7):1674-1686. doi: 10.1158/1078-0432.CCR-14-2890. Epub 2015 Nov 23.

29.

Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer.

Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS.

Head Neck. 2016 Apr;38 Suppl 1:E1554-61. doi: 10.1002/hed.24278. Epub 2015 Nov 23.

PMID:
26595157
30.

Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.

Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA.

Clin Cancer Res. 2015 Nov 1;21(21):4831-44. doi: 10.1158/1078-0432.CCR-15-0279. Epub 2015 Jun 29.

31.

Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.

Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM.

Anticancer Drugs. 2015 Sep;26(8):835-42. doi: 10.1097/CAD.0000000000000251.

32.

drexplorer: A tool to explore dose-response relationships and drug-drug interactions.

Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J.

Bioinformatics. 2015 May 15;31(10):1692-4. doi: 10.1093/bioinformatics/btv028. Epub 2015 Jan 18.

33.

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.

Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B.

Cancer Lett. 2015 Feb 1;357(1):179-185. doi: 10.1016/j.canlet.2014.11.024. Epub 2014 Nov 18.

34.

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.

Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP.

Clin Cancer Res. 2015 Feb 15;21(4):693-700. doi: 10.1158/1078-0432.CCR-14-0265. Epub 2014 Sep 10.

35.

A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM.

Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.

36.

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM.

Oncologist. 2014 Oct;19(10):1040-1. doi: 10.1634/theoncologist.2014-0228. Epub 2014 Aug 28.

37.

Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options.

Recondo G Jr, Busaidy N, Erasmus J, Williams MD, Johnson FM.

Head Neck. 2015 May;37(5):746-54. doi: 10.1002/hed.23634. Epub 2014 May 5. Review.

PMID:
24677409
38.

Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.

Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY.

J Natl Cancer Inst. 2013 Oct 16;105(20):1558-70. doi: 10.1093/jnci/djt263. Epub 2013 Oct 3.

39.

Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.

Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM.

J Transl Med. 2013 Aug 27;11:198. doi: 10.1186/1479-5876-11-198. Erratum in: J Transl Med. 2014;12:67. Lai, Stephen Y [added].

40.

Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.

Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V.

Lung Cancer. 2013 Jun;80(3):235-41. doi: 10.1016/j.lungcan.2013.01.018. Epub 2013 Feb 26. Review.

PMID:
23485129
41.

Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC.

Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A.

J Thorac Oncol. 2013 Mar;8(3):301-8. doi: 10.1097/JTO.0b013e318282def7.

42.

Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.

Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN.

Head Neck. 2013 Oct;35(10):1454-60. doi: 10.1002/hed.23173. Epub 2012 Sep 28.

PMID:
23018868
43.

Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.

Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK.

Radiother Oncol. 2012 Nov;105(2):241-9. doi: 10.1016/j.radonc.2012.08.010. Epub 2012 Sep 23.

PMID:
23010482
44.

Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.

Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM.

Mol Cancer Ther. 2012 Sep;11(9):2021-32. doi: 10.1158/1535-7163.MCT-12-0030. Epub 2012 Jul 17.

45.

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM.

Sci Transl Med. 2012 May 30;4(136):136ra70. doi: 10.1126/scitranslmed.3003513.

46.

STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma.

Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM.

Clin Cancer Res. 2012 Jan 1;18(1):127-39. doi: 10.1158/1078-0432.CCR-11-1889. Epub 2011 Nov 16.

47.

Regulation of SRC family kinases in human cancers.

Sen B, Johnson FM.

J Signal Transduct. 2011;2011:865819. doi: 10.1155/2011/865819. Epub 2011 Apr 4.

48.

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.

Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA.

Cancer. 2011 May 15;117(10):2112-9. doi: 10.1002/cncr.25769. Epub 2010 Nov 29. Erratum in: Cancer. 2012 May 1;118(9):2560. Johnson, Faye M [added].

49.

Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.

Sen B, Peng S, Saigal B, Williams MD, Johnson FM.

Clin Cancer Res. 2011 Feb 1;17(3):514-24. doi: 10.1158/1078-0432.CCR-10-1617. Epub 2010 Nov 24.

50.

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ.

J Clin Oncol. 2010 Oct 20;28(30):4609-15. doi: 10.1200/JCO.2010.30.5474. Epub 2010 Sep 20.

Supplemental Content

Loading ...
Support Center